Two more recent RCTs tested the combined SGLT1 and SGLT2 inhibitor sotagliflozin in individuals with T2D, i.e. SOLOIST-WHF and SCORED. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.